

## Review

# Regulators of Cholangiocyte Proliferation

Chad Hall,\*†‡ Keisaku Sato,§ Nan Wu,§ Tianhao Zhou,§ Konstantina Kyritsi,§ Fanyin Meng,\*§¶  
Shannon Glaser,\*§¶ and Gianfranco Alpini‡§¶

\*Research, Central Texas Veterans Health Care System, Temple, TX, USA

†Baylor Scott & White Digestive Disease Research Center, Temple, TX, USA

‡Department of Surgery, Baylor Scott & White and Texas A&M Health Science Center, Temple, TX, USA

§Operational Funds, Baylor Scott & White, Temple, TX, USA

¶Department of Medicine, Baylor Scott & White and Texas A&M Health Science Center, Temple, TX, USA

Cholangiocytes, a small population of cells within the normal liver, have been the focus of a significant amount of research over the past two decades because of their involvement in cholangiopathies such as primary sclerosing cholangitis and primary biliary cholangitis. This article summarizes landmark studies in the field of cholangiocyte physiology and aims to provide an updated review of biliary pathogenesis. The historical approach of rodent extrahepatic bile duct ligation and the relatively recent utilization of transgenic mice have led to significant discoveries in cholangiocyte pathophysiology. Cholangiocyte physiology is a complex system based on heterogeneity within the biliary tree and a number of signaling pathways that serve to regulate bile composition. Studies have expanded the list of neuropeptides, neurotransmitters, and hormones that have been shown to be key regulators of proliferation and biliary damage. The peptide histamine and hormones, such as melatonin and angiotensin, as well as numerous sex hormones, have been implicated in cholangiocyte proliferation during cholestasis. Numerous pathways promote cholangiocyte proliferation during cholestasis, and there is growing evidence to suggest that cholangiocyte proliferation may promote hepatic fibrosis. These pathways may represent significant therapeutic potential for a subset of cholestatic liver diseases that currently lack effective therapies.

**Key words:** Biliary epithelium; Cholangiopathies; Cholestasis; Liver damage

### ANATOMY/PHYSIOLOGY

The liver is primarily composed of two types of epithelial cells: hepatocytes and cholangiocytes<sup>1</sup>. The liver is primarily responsible for the bile acid production, serum detoxification, serum protein and cholesterol production, coagulation cascade maintenance, and glucose storage<sup>1</sup>. Hepatocytes make up 70% of the liver's parenchyma and perform the majority of these functions<sup>2</sup>. Cholangiocytes account for 3%–5% of the endogenous liver cell population and form the biliary tree that begins as small intrahepatic ductules and terminates as the larger extrahepatic bile ducts<sup>3</sup>. Bile is secreted across the apical membrane of hepatocytes into canaliculi formed between adjacent cells<sup>4</sup>. Bile flows through the canaliculi and the canals of Hering into the small biliary ductules that ultimately

results in bile secretion into the small intestine through the ampulla of Vater<sup>5</sup>. Despite providing only a fraction of the total liver cell population, cholangiocytes play an important physiologic role in altering ductal bile composition as it travels through the biliary system<sup>6,7</sup>. This process involves the secretion and absorption of water, electrolytes, and other organic solutes from hepatocellular bile<sup>6–8</sup>. This process is mediated by a series of hormone-regulated Ca<sup>2+</sup>-dependent or cyclic adenosine 3',5'-monophosphate (cAMP)-dependent resorptive and secretory events<sup>6,7,9–13</sup>.

### Heterogeneity of the Biliary Tree

Heterogeneity in cholangiocyte structure and function has been defined throughout the biliary tree of

Address correspondence to Gianfranco Alpini, Ph.D., Central Texas Veterans Health Care System, Texas A&M Health Science Center College of Medicine, Olin E. Teague Medical Center, 1901 South 1st Street, Building 205, 1R60, Temple, TX 76704, USA. Tel: 254-743-2625, 254-743-1044; Fax: 254-743-0378, 254-743-0555; E-mail: [galpini@medicine.tamhsc.edu](mailto:galpini@medicine.tamhsc.edu)


rodents and humans<sup>3,9,13</sup>. Structurally, cholangiocytes take on the shape and size necessary to maintain the integrity of the biliary epithelium. In humans, intrahepatic bile ducts range in size from small ductules (<15  $\mu\text{m}$ ) to large hepatic ducts (>800  $\mu\text{m}$ )<sup>3</sup>. Cholangiocytes in larger ducts tend to be larger and more cuboidal in shape than cholangiocytes of small intrahepatic bile ducts<sup>14–16</sup>. Only large cholangiocytes from rodents are cAMP responsive and express secretin receptors (SRs), cystic fibrosis transmembrane conductance regulator (CFTR), and the chloride bicarbonate anion exchanger 2 ( $\text{Cl}^-/\text{HCO}_3^-$  AE2)<sup>3,9,13,17,18</sup>. Activation of AE2 leads to changes in ductal secretion of water and electrolytes including  $\text{HCO}_3^-$  ions<sup>5</sup>. Expression of the SR is a key factor regulating the secretory and proliferative activities of cholangiocytes and heterogeneity of the biliary tree. Cholangiocytes proliferate in response to biliary injury, such as extrahepatic obstruction and cholestatic liver diseases, and in response to alcohol, toxins, or drugs<sup>19</sup>. Using a rat model of extrahepatic cholestasis induced by bile duct ligation (BDL), studies have shown that cholangiocyte proliferation is limited to large bile ducts and is closely associated with SR gene expression and secretin-stimulated cAMP levels<sup>11,12</sup>. Figure 1 highlights the heterogeneity within the biliary tree and the response of small and large cholangiocytes during cholestasis.

Electron microscopic studies have shown that small cholangiocytes display a larger nucleus: cytoplasm ratio compared to large cholangiocytes, suggesting that small

cholangiocytes represent a hepatic progenitor cell population<sup>20</sup>. Small cholangiocytes do not express the SR and do not actively proliferate following cholestatic injury (BDL), but they are capable of proliferating [by amplification of inositol 1,4,5-triphosphate ( $\text{IP}_3$ )/ $\text{Ca}^{2+}$ -dependent signaling]<sup>20,21</sup> and differentiating into a large cholangiocyte phenotype under specific pathological conditions associated with damage of large cAMP-responsive bile ducts, such as  $\gamma$ -aminobutyric acid-induced liver injury<sup>10,21–23</sup>. Additionally, small cholangiocytes have been shown to express a senescent phenotype in humans with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)<sup>24,25</sup>. Despite this understanding of biliary heterogeneity, the correlation of cholangiocyte phenotype to disease progression remains an area of investigation.

#### Bicarbonate Secretion

The excretion of bicarbonate into ductal bile remains one of the most important and well-studied functions of cholangiocytes. This process is stimulated by activation of the SR by its ligand, secretin, a 27-amino acid gastrointestinal peptide hormone. SRs are expressed only on the basolateral membrane of large cholangiocytes<sup>26,27</sup>. The SR is a G protein-coupled receptor (GPCR) that promotes bicarbonate excretion through a series of events activating adenylyl cyclase 8 and protein kinase A (PKA)<sup>28,29</sup>. Activated PKA promotes the phosphorylation of CFTR, which triggers opening of the  $\text{Cl}^-$  channel and leads to secretion of the chloride ion at the apical membrane of cholangiocytes, depolarizing the cell



**Figure 1.** Heterogeneity within the biliary tree. Large cholangiocytes are cAMP responsive and express SR, CFTR, and AE2 that regulate bile homeostasis. Large cholangiocytes proliferate in response to cholestatic liver injury. Small cholangiocytes do not proliferate during cholestasis but may act as a progenitor cell population and differentiate into large cholangiocytes via the  $\text{IP}_3/\text{Ca}^{2+}$  signaling pathways.

membrane<sup>30,31</sup>. This ion gradient promotes activation of the  $\text{Cl}^-/\text{HCO}_3^-$  exchanger, resulting in secretin-stimulated bicarbonate-enriched bile<sup>7</sup>. The secretion of  $\text{HCO}_3^-$  creates an AE2-dependent bicarbonate-rich umbrella and serves as a protective mechanism against the cytotoxicity of hydrophobic bile salts<sup>32</sup>. Not only does the SR regulate bicarbonate secretion but also is a key regulator in cholangiocyte proliferation.

### MECHANISMS AND REGULATORS OF CHOLANGIOCYTE PROLIFERATION

Intracellular cAMP signaling plays an important role in cholangiocyte proliferation. Chronic administration of forskolin (an adenylate cyclase activator) to normal rats increased intrahepatic bile duct mass, cAMP levels, and secretin-induced choleresis following BDL<sup>33</sup>. Cholangiocyte proliferation was associated with increased activity of the PKA–Src–MEK–ERK1/2 pathway<sup>33</sup>. Ablation of this pathway using specific inhibitors resulted in decreased cholangiocyte proliferation<sup>33</sup>.

Additionally, bile acid-induced activation of receptor tyrosine kinases, specifically the epidermal growth factor receptor (EGFR), has been shown to stimulate human cholangiocyte proliferation via transforming growth factor- $\alpha$  (TGF- $\alpha$ )-dependent mechanisms<sup>34</sup>. Tyrosine kinase signaling via EGFR has also been demonstrated in cholangiocarcinoma cells<sup>35</sup>, and the development of ROS kinase fusions may contribute to cholangiocarcinoma oncogenesis<sup>36</sup>. The Janus kinase/signal transducer activator of transcription (JAK/STAT) pathway has also been implicated in cholangiocarcinoma growth, and inhibition of this pathway with sorafenib has been shown to accelerate dephosphorylation of STAT3<sup>37</sup>.


Recent studies have expanded our knowledge of biliary secretion and the role of cilia in this process. Cholangiocytes possess cilia on their apical surface that act as mechanoreceptors, chemosensors, and osmosensors<sup>38</sup>. Shear stress along the apical membrane of cholangiocytes is detected by cilia, resulting in upregulation of  $\text{Cl}^-$  currents via TMEM16A (aka anoctamin), a  $\text{Ca}^{2+}$ -activated  $\text{Cl}^-$  channel<sup>39</sup>. This process is dependent on PKC- $\alpha$ , extracellular ATP, purinergic P2 receptors, and increases in intracellular  $\text{Ca}^{2+}$  concentration<sup>39</sup>. Inhibition of CFTR did not change flow-stimulated currents in their studies, suggesting a different mechanism of  $\text{Cl}^-$  transport when cholangiocytes are exposed to shear forces<sup>39</sup>. The key proteins involved in mechanosensation are polycystin-1 and polycystin-2. These proteins form a functional complex allowing  $\text{Ca}^{2+}$  influx, influencing secretory and proliferative functions. Cholangiocytes also function as chemosensors, capable of detecting changes in concentrations of molecules within the bile. The P2Y receptors, including P2Y12, activate intracellular calcium and cAMP signaling cascades when

activated by nucleotides present in large concentrations in the bile<sup>38,40</sup>.

Numerous animal models of biliary hyperplasia, such as BDL, partial hepatectomy, chronic bile acid feeding (e.g., taurocholic acid), and cirrhosis induced by carbon tetrachloride ( $\text{CCl}_4$ ), have enabled researchers to greatly expand our knowledge of biliary proliferation and the response of cholangiocytes to biliary injury<sup>7,41–44</sup>. The use of transgenic mice, such as the *Mdr2*<sup>-/-</sup>, has also provided insight into the mechanisms of cholestatic liver injury. These mice serve as an animal model of sclerosing cholangitis because their loss of *Mdr2* (a flippase) significantly reduces biliary phospholipid secretion and increases levels of nonmicellar bile acids that subsequently cause biliary injury with proliferation, pericholangitis, and fibrosis<sup>5,45</sup>. These models have contributed to several studies demonstrating that cholangiocytes display a neuroendocrine phenotype in response to biliary injury<sup>46</sup>. This phenotype allows cholangiocytes to secrete and respond to a number of hormones, neuropeptides, and neurotransmitters that regulate cholangiocyte proliferation. A list of the neuroendocrine modulators that regulate cholangiocyte proliferation is shown in Table 1. Figure 2 highlights how these modulators interact with cholangiocyte receptors to initiate proliferation during cholestasis. These pathways may provide novel therapeutic strategies to chronic cholestatic liver diseases, such as PBC and PSC<sup>47</sup>. In the remaining sections, we will review the neuroendocrine properties of cholangiocytes and discuss their involvement in cholangiocyte proliferation, cholestatic liver disease, and hepatic fibrosis.

#### Gastrointestinal Hormones

*Secretin.* As previously mentioned, the role of secretin in response to biliary injury has been widely studied. The SR is upregulated in cholangiocytes in response to biliary injury; however, little was known about secretin's role in biliary proliferation until the development of a SR knockout (*SR*<sup>-/-</sup>) transgenic mouse. Glaser et al. demonstrated that knockout of the SR significantly reduced large intrahepatic bile duct mass in mice following BDL<sup>48</sup>. This was associated with increased cholangiocyte apoptosis and decreased markers of proliferation, as well as decreased ERK1/2 phosphorylation<sup>48</sup>. Furthermore, chronic treatment of normal rats with secretin significantly increased bile duct mass and cholangiocyte proliferation, a process that was inhibited with PKA and MAPK inhibitors<sup>49</sup>. These findings suggest that the SR has an important role in maintaining cholangiocyte growth. In a more recent study, we have demonstrated that secretin secretion from cholangiocytes and duodenal S cells is capable of decreasing miR-125 and let-7 levels, promoting an increase in vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) causing enhanced biliary



**Figure 2.** Large cholangiocytes maintain bile homeostasis under normal conditions via the  $\text{Cl}^-/\text{HCO}_3^-$  exchanger. During cholestasis, many peptides, hormones, and neurotransmitters act on cholangiocyte receptors to modulate cell proliferation via cAMP/PKA/ERK1/2 signaling pathways.

hyperplasia<sup>18</sup>. Additionally, we have recently presented our data that showed treatment of *Mdr2*<sup>-/-</sup> mice with an SR antagonist significantly decreased biliary hyperplasia, bile duct mass, liver fibrosis, and expression of profibrotic genes<sup>50</sup>. We have also shown that the SR axis contributes to cholestatic-induced liver fibrosis through TGF- $\beta$ 1 signaling<sup>51</sup>.

*Somatostatin.* Other gastrointestinal hormones, such as somatostatin and gastrin, inhibit the response of cholangiocytes to secretin by inhibiting secretin-induced

intracellular cAMP levels and bicarbonate excretion<sup>6,52,53</sup>. Somatostatin also decreases cholangiocyte proliferation via interaction with somatostatin receptor subtype 2 (SSTR2)<sup>12,54</sup>. The somatostatin analog octreotide has also been shown to decrease biliary fibrosis following extrahepatic biliary obstruction<sup>54</sup>. Studies with octreotide have also been performed in a murine model of polycystic liver disease. Administration of octreotide in these animals decreased cAMP content, limited cyst growth, and inhibited hepatic disease progression<sup>55</sup>. This parallels results of

**Table 1.** Neuroendocrine Factors Affecting Cholangiocyte Proliferation

Class/Modulator	Receptor	Effect on Proliferation	References
<b>Gastrointestinal hormones</b>			
Secretin	SR	Maintains bile duct mass; promotes large cholangiocyte proliferation during cholestasis	48–50
Somatostatin	SSTR2	Inhibits proliferation; counteracts secretin during cholestasis	52–56
Gastrin	CCK-B	Inhibits proliferation; reverses cholangiocyte response to BDL	53,57
GLP-1	GLP-1R	Increases proliferation	59–61
<b>Bile acids</b>			
Taurocholate		Increased proliferation, SR expression, and bile flow	43,62
Taurolithocholate		Increased proliferation, SR expression, and bile flow	43,62
Ursodeoxycholic acid		Decreased proliferation and secretion after BDL	65,66
Tauroursodeoxycholic acid		Decreased proliferation and secretion after BDL	65,66
<b>Angiogenic factors</b>			
VEGF-A and VEGF-C	VEGFR-2, VEGFR-3	Increase proliferation and fibrosis following BDL	69–72
Ang-1	Tie-2	Synergic with VEGF to induce proliferation	73
PDGF	PDGFR	Unknown effect on proliferation; promotes stellate cell activation after BDL	82,83
<b>Neurotransmitters</b>			
Acetylcholine	M3	Increases proliferation and secretin-induced secretion following BDL	86,87
Adrenergic stimulators (forskolin, clenbuterol, and dobutamine)	$\beta$ 1 and $\beta$ 2	Increases proliferation	33,87,89
Phenylephrine	$\alpha$ 1	Increases small cholangiocyte proliferation	88
Dopamine	D2	Inhibits secretin effects after BDL	90
Serotonin	1A and 1B	Inhibits proliferation, fibrogenic effects on stellate cells	92,93
Histamine	HRH1, HRH2, HRH3, HRH4	Decreases proliferation after BDL; small cholangiocytes proliferation with HRH1 agonist	95–98
$\alpha$ CGRP	CLR, RAMP1, RCP	Increases proliferation following BDL	100
Substance P	NK-1R	Increases proliferation	101
NGF	TkrA	Sustains proliferation following BDL	102
Melatonin	MT1, MT2	Decreases bile duct mass and proliferation following BDL	103–105
<b>Sex hormones</b>			
Estrogen	ER- $\alpha$ , ER- $\beta$	Stimulates proliferation	107–109
Progesterone	PRGMC1, PRGMC2, mPR $\alpha$	Increase bile duct mass and proliferation following BDL	112
FSH	FSHR	Increase bile duct mass and proliferation following BDL	113,114
GnRH	GnRHR <sub>1</sub> , GnRHR <sub>2</sub>	Stimulates proliferation	116
Prolactin	Long, short	Stimulates proliferation	117
<b>Other hormones</b>			
Iodothyronine (T3)	$\alpha$ <sub>1</sub> -, $\alpha$ <sub>2</sub> -, $\beta$ <sub>1</sub> -, and $\beta$ <sub>2</sub> -THR	Decreased proliferation after BDL	118
Angiotensin II	Angiotensin receptor type 1	Increases proliferation and fibrosis following BDL	119

a double-blinded, randomized controlled trial in humans with liver manifestations of autosomal dominant polycystic kidney disease (ADPKD). Patients treated with octreotide for 6 months showed significant reductions in liver volumes after 6 months of therapy compared to placebo treatment<sup>56</sup>.

**Gastrin.** The primary role of gastrin is to stimulate acid secretion from gastric parietal cells and stimulate acid-secreting mucosal growth in the stomach; however, trophic effects of gastrin have also been reported in the colon, duodenum, and pancreas<sup>57</sup>. Similar to somatostatin in the liver, gastrin has been shown to inhibit secretin-induced bicarbonate secretion and reduce secretin-induced cAMP levels by interacting with cholecystokinin-B (CCK-B) receptors<sup>53</sup>. Chronic administration of gastrin has also been shown to inhibit cholangiocyte proliferation, and administration of gastrin following BDL resulted in a reversal of cholangiocyte proliferation in rats<sup>53,58</sup>. The conclusions from these early studies suggest that gastrin may be beneficial to cholangiocytes during cholestasis; however, more studies are needed to determine if gastrin can limit the ductular reaction associated with cholestasis and provide a therapeutic benefit.

**Glucagon-Like Peptide 1.** Glucagon-like peptide 1 (GLP-1) is a peptide hormone released from neuroendocrine cells that stimulate a variety of neuroendocrine mechanisms, such as pancreatic  $\beta$ -cell proliferation, islet cell neurogenesis, and the neuroendocrine transdifferentiation of pancreatic ductal cells<sup>59,60</sup>. Studies have shown that cholangiocytes express the GLP-1 receptor (GLP-1R), and expression of the receptor is upregulated during the progression of cholestasis. Cholangiocytes also synthesize and release GLP-1 during times of proliferation, which acts locally in the cholangiocyte microenvironment<sup>61</sup>. Activation of GLP-1R via GLP-1 or a selective receptor agonist, exendin-4, stimulates biliary growth, which is mediated through the phosphatidylinositol 3-kinase (PI3K), cAMP/PKA, and  $Ca^{2+}$ -CamKII $\alpha$  pathway<sup>60</sup>. Administration of a GLP-1R antagonist demonstrates a marked reduction in bile duct mass in rats following BDL<sup>61</sup>.

**Bile Acids.** Bile acids accumulate during cholestasis and are capable of producing physiologic effects in cholangiocytes related to proliferation, secretion, and cell signaling. Administration of taurocholate (TC) and taurothiocholate (TLC) stimulated large cholangiocyte proliferation in vitro and in vivo<sup>43,62</sup>. This was associated with increased SR gene expression, secretin-induced cAMP levels and secretin-stimulated bile flow, and bicarbonate secretion<sup>43</sup>. Further studies have also shown that bile acids stimulate expression of the  $Na^+$ -dependent apical bile acid transporter (ASBT) in small and large rat cholangiocytes, which was dependent on PKC activation<sup>63</sup>. Cholangiocyte proliferation and secretion in response

to bile acids during cholestasis are promoted through a PI3K-dependent pathway<sup>64</sup>. Furthermore, secretin has been shown to promote cholehepatic shunting of conjugated bile acids through increased expression of ASBT<sup>17</sup>. Treatment of rats with ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA) following BDL significantly reduced cholangiocyte proliferation and secretion through activation of  $Ca^{2+}$ -dependent PKC- $\alpha$ <sup>65</sup>. Furthermore, UDCA and TUDCA were shown to be cytoprotective in rats following BDL+vagotomy, a model that induces cholestasis and bile duct loss through apoptosis of cholangiocytes<sup>66</sup>. Treatment of these rats with UDCA and TUDCA prevented cholangiocyte apoptosis by calcium-dependent MAPK and PI3K pathways<sup>66</sup>.

Many studies have contributed to our knowledge of bile acid physiology through other cholestatic models. For instance, Fickert et al. showed that 24-norursodeoxycholic (norUDCA), a C(23) homolog of UDCA, is capable of ameliorating sclerosing cholangitis in *Mdr2*<sup>-/-</sup> mice<sup>45</sup>. norUDCA is relatively resistant to conjugation and participates in a cholehepatic shunting process that sets up a bile acid-dependent, bicarbonate-rich choleresis<sup>67</sup>. Randomized controlled trials are currently underway using norUDCA for the management of PSC<sup>67</sup>. UDCA has remained the only approved pharmacotherapy for PBC for nearly two decades; however, many new therapies are currently being developed based on UDCA combination therapies<sup>68</sup>.

#### *Angiogenic Factors*

**Vascular Endothelial Growth Factor.** Cholangiocytes receive their blood supply from a complex microvascular network termed the peribiliary plexus, which stems from branches of hepatic arteries<sup>69</sup>. A key study has shown that this network enlarges following BDL, suggesting that biliary vascular supply contributes partly to cholangiocyte proliferation and response to biliary injury. They further demonstrated that secretion of VEGF-A and VEGF-C, and expression of their corresponding receptors are upregulated following BDL<sup>69</sup>. VEGF-A and VEGF-C induce cholangiocyte proliferation via activation of  $IP_3/Ca^{2+}/PKC-\alpha$  and phosphorylation of Src/ERK1/2 pathways<sup>70</sup>. Administration of anti-VEGF-A and/or anti-VEGF-C and hepatic artery ligation inhibited the ductular reaction following BDL<sup>69</sup>. Administration of r-VEGF-A to hepatic artery-ligated rats induced ductular reaction following BDL<sup>71</sup>. Studies have also identified a link between bile acid signaling and VEGF expression in cholangiocytes. Mancinelli et al. showed that TC feeding to BDL rats prevented bile duct damage induced by caffeic acid, which is known to inhibit growth of many cell types<sup>72</sup>. The protective effect of TC was associated with increased expression of VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3<sup>72</sup>.

This work has also been replicated in other forms of human biliary disease, such as polycystic liver disease. Cholangiocyte epithelium from humans with polycystic liver disease strongly expresses VEGF and their corresponding receptors. VEGF not only induced cholangiocyte proliferation and cyst growth but also increased the density of the portal vasculature<sup>73</sup>. Furthermore, treatment of polycystic liver disease mice (WS25/–) with a potent VEGF receptor inhibitor (MU-5416) significantly decreased cyst growth and liver density<sup>74</sup>. Studies in PBC have also demonstrated strong upregulation of VEGF-A, as well as other angiogenic factors, which likely induce angiogenesis near injured bile ducts, contributing to inflammatory cell recruitment and disease progression<sup>75</sup>. These findings indicate that the autocrine/paracrine mechanisms of VEGF affect a variety of biliary pathologies.

Additionally, authors have demonstrated that VEGF plays an important role in hepatic regeneration following partial hepatectomy. Wang et al. demonstrated that liver sinusoidal endothelial progenitor cells (LSECs) are responsible for promoting liver regeneration in rats following partial hepatectomy<sup>76</sup>. These progenitor cells are recruited from the bone marrow as bone marrow-derived liver sinusoidal endothelial cell progenitor cells (BM SPCs) via a recruitment system that is regulated by hepatic VEGF<sup>77</sup>. Knockout of hepatic VEGF with oligonucleotides inhibited proliferation and recruitment of BM SPCs to the liver parenchyma<sup>77</sup>. DeLeve et al. have recently demonstrated that VEGF acts through stromal cell-derived factor-1 (SDF-1) to mediate recruitment of bone marrow-derived progenitor cells to the liver sinusoids following partial hepatectomy<sup>78</sup>. It appears that VEGF not only regulates cholangiocyte proliferation but also is vital for liver regeneration and reestablishing normal endothelial architecture following partial hepatectomy.

*Angiopoietins.* Another class of angiogenic factors, the angiopoietins, also plays a role in cholestatic liver injury. Angiopoietin-1 and -2 (Ang-1 and Ang-2) act through the tyrosine kinase receptor Tie-2 but have opposite effects. Ang-1 promotes tyrosine phosphorylation, and Ang-2 is a receptor antagonist. Whereas VEGF has been implicated in vasculogenesis, studies have demonstrated that Ang-1 is responsible for maturation of newly formed vessels by recruitment of mural pericytes<sup>79</sup>. Similar to VEGF, the angiopoietins are also upregulated during hepatic disease states. Cholangiocytes isolated from patients with ADPKD express Ang-1 and Ang-2 as well as Tie-2<sup>73</sup>. Fabris et al. demonstrated that Ang-1 alone did not promote cholangiocyte proliferation but was synergistic with VEGF<sup>73</sup>. PBC patients express high levels of VEGF-1, Ang-1, Ang-2, and Tie-2 on endothelial cells and periportal hepatocytes, which promotes angiogenesis near damaged bile ducts<sup>80</sup>.

*Platelet-Derived Growth Factor.* Platelet-derived growth factor (PDGF) is a polypeptide growth factor involved in numerous biological processes including the activity of mesenchymal cells to regulate matrix metabolism, chemotactic and vasoactive properties, as well as moderation of the inflammatory response to cellular injury<sup>81</sup>. Pinzani et al. demonstrated that PDGF and its receptor, PDGF-R, are overexpressed in human liver fibrogenesis<sup>81</sup>. Using BDL rats as a model of cholestasis, Grappone et al. further characterized PDGF expression and demonstrated that the  $\beta$ -chain is synthesized by cholangiocytes during cholestasis, and its receptor is primarily located on hepatic stellate cells<sup>82</sup>. These findings signified a cross-talking mechanism between cholangiocytes and hepatic stellate cells during cholestasis that may contribute to liver fibrosis. Furthermore, Kinnman et al. showed that PDGF initiates chemotaxis of hepatic stellate cells toward bile duct structures during cholestasis<sup>83</sup>. Another study by Kinnman et al. showed that peribiliary cells undergo a PDGF-mediated conversion into myofibroblasts that contribute to cholestatic liver fibrosis<sup>84</sup>. In a more recent study, the  $\beta$ -PDGFR expressed on hepatic stellate cells has been shown to be a key regulator of hepatic injury and fibrosis in a CCl<sub>4</sub> model of cholestatic liver injury<sup>85</sup>.

#### *Neuropeptides and Neurotransmitters*

*Acetylcholine.* Nearly two decades ago, Alvaro et al. demonstrated that cholangiocytes express the M3 acetylcholine receptor, and acetylcholine works through this receptor to enhance the activity of the secretin-induced Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> ion exchanger by a Ca<sup>2+</sup>-dependent PKC-insensitive pathway that potentiates the stimulation of adenylyl cyclase<sup>86</sup>. Furthermore, vagotomy impairs cholangiocyte proliferation, enhances apoptosis, and limits ductular reaction following BDL in rats<sup>87</sup>. Vagotomy was also associated with decreased cAMP levels and secretin-induced choleresis following BDL. Forskolin treatment following vagotomy and BDL prevented the decrease in cAMP levels and maintained cholangiocyte proliferation<sup>87</sup>.

*Adrenergic Fibers.* Previous studies have demonstrated that sympathetic nerve activity is required for liver and cholangiocyte regeneration after partial hepatectomy<sup>88</sup>. Additionally, invoking adrenergic denervation to BDL rats using 6-hydroxydopamine decreased cholangiocyte proliferation and secretin-dependent secretion while increasing cholangiocyte apoptosis via decreasing cAMP levels<sup>89</sup>. Administration of an adenylyl cyclase activator or  $\beta$ 1 and  $\beta$ 2 agonists (forskolin, clenbuterol, and dobutamine, respectively) maintained normal cholangiocyte secretory and proliferative responses to BDL via phosphorylation of Akt<sup>89</sup>. Taurocholic acid prevented the induction of apoptosis in rats subjected to BDL plus autonomic denervation by preventing Akt dephosphorylation.

Additionally, Alpini et al. demonstrated heterogeneity within the biliary tree in response to adrenergic stimulation. Small, but not large, cholangiocytes proliferate in response to phenylephrine via  $IP_3/Ca^{2+}$ -dependent signaling pathways and activation of nuclear factor of activated T cells 2 (NFAT2) and specificity protein 1 (SP1)<sup>10</sup>.

**Dopamine.** Cholangiocytes also express the D2 dopamine receptor (but not D1 or D3) on their basolateral surface<sup>90</sup>. Selective stimulation of this receptor increased intracellular  $IP_3$  and  $Ca^{2+}$  levels, inhibited secretin-stimulated bicarbonate-rich choleresis in BDL rats, and inhibited secretin-induced cAMP levels and PKA activity in purified cholangiocytes<sup>90</sup>. Additional studies demonstrated that dopamine works through the D2 receptor to inhibit secretin's effects by increasing PKC- $\gamma$  expression<sup>90</sup>. It is reasonable to hypothesize from these studies that dopamine may also regulate cholangiocyte proliferation in response to cholestasis; however, this has not been reported in a cholestasis model. Studies have shown that dopamine is secreted from cultured cholangiocarcinoma cells, and these cells proliferate in response to D2 and D4 receptor agonists<sup>91</sup>. More studies are needed to determine dopamine's role in cholestasis-induced cholangiocyte proliferation and hepatic fibrosis.

**Serotonin.** Serotonin is a neuroendocrine hormone secreted from enterochromaffin cells throughout the gastrointestinal tract. Marzioni et al. demonstrated that cholangiocytes secrete serotonin and express the serotonin 1A and serotonin 1B receptors<sup>92</sup>. Activation of these receptors significantly inhibits cholangiocyte proliferation and choleresis in BDL rats, which is mediated by enhanced D-myo- $IP_3/Ca^{2+}/PKC$  signaling and the consequent inhibition of the cAMP/PKA/Src/ERK1/2 signaling cascade<sup>92</sup>. This suggests that a serotonin-mediated autocrine loop is capable of limiting biliary growth and subsequent ductular reaction during cholestasis. A recent study using tryptophan hydroxylase-2 knock-in (TPH2KI) mice demonstrated that serotonin is vital for remodeling injured bile ducts, and mice with reduced biliary serotonin levels exhibit excessive cholangiocyte proliferation, duct accumulation, and liver fibrosis following BDL<sup>93</sup>. The same study also demonstrated that serotonin stimulates myofibroblast production of TGF- $\beta$ 1, which decreases tryptophan hydroxylase-2 (TPH2) expression and subsequently decreases serotonin levels and its effects on cholangiocyte proliferation<sup>93</sup>. A recent review by Mann et al. highlights these findings and further emphasizes the point that serotonin is involved in a complex network of pathways between cholangiocytes, myofibroblasts, and hepatocytes that regulates liver fibrosis through TGF- $\beta$ 1 signaling<sup>94</sup>.

**Histamine.** Histamine is an aminergic peptide and neurotransmitter that has also been identified to regulate cholangiocyte proliferation in response to biliary injury.

Histamine acts through a variety of G protein-coupled histamine receptor subtypes (HRH1, HRH2, HRH3, and HRH4) that are all expressed in normal and BDL cholangiocytes<sup>95</sup>. Francis et al. demonstrated that expression of HRH3 is significantly upregulated in proliferating cholangiocytes following BDL and chronic stimulation of this receptor with a selective agonist decreased biliary growth following BDL, whereas a selective HRH3 antagonist treatment increased cholangiocyte hyperplasia<sup>95</sup>. Activation of HRH3 was associated with increased cAMP levels and PKA/ERK1/2/ELK-1 phosphorylation<sup>95</sup>. Furthermore, performing BDL in histidine decarboxylase knockout mice ( $HDC^{-/-}$ ) demonstrated that inhibiting the pathway for histamine production decreased cholangiocyte proliferation and VEGF/HIF-1 $\alpha$  expression via decreasing PKA/ERK1/2 activation<sup>96</sup>. Kennedy et al. also demonstrated that histamine derived from mast cells within the liver also contribute to biliary proliferation following BDL. Cromolyn-treated BDL mice displayed decreased bile duct mass and biliary proliferation<sup>97</sup>. Also, exposure of cholangiocytes with supernatants from cromolyn-treated mast cells significantly reduced cholangiocyte proliferation in vitro<sup>97</sup>.

Francis et al. also demonstrated that heterogeneity exists between large and small cholangiocytes in relation to histamine's effects on cholangiocyte proliferation. This study showed that small, but not large, cholangiocytes proliferate in response to an HRH1 agonist via an  $IP_3/Ca^{2+}$ -dependent signaling pathway<sup>98</sup>. Treatment of small cholangiocytes with a selective HRH1 antagonist successfully reduced proliferation<sup>98</sup>. Furthermore, another study demonstrated that histamine stimulates proliferation of large rat cholangiocytes, but not small cholangiocytes, via activation of HRH2 through a cAMP-dependent signaling mechanism<sup>23</sup>. In another study, Kennedy et al. demonstrated that administration of histamine following BDL +  $CCl_4$  treatment successfully restored large cholangiocyte proliferative capacity, further demonstrating histamine's effects on cholangiocyte proliferation and homeostasis<sup>99</sup>.

**$\alpha$ -Type Calcitonin Gene-Related Peptide.** In addition to parasympathetic and sympathetic regulators of biliary proliferation, the sensory neuropeptide  $\alpha$ -type calcitonin gene-related peptide ( $\alpha$ CGRP) has also been shown to regulate cholangiocyte proliferation during cholestasis. In a  $\alpha$ CGRP knockout mouse model, Glaser et al. demonstrated that biliary proliferation is inhibited via decreased levels of cAMP and PKA following BDL<sup>100</sup>. In vitro,  $\alpha$ CGRP and  $\beta$ CGRP induced cholangiocyte proliferation and increased cAMP/PKA levels<sup>100</sup>.

**Substance P.** Substance P (SP) is a member of the tachykinin peptide family that preferentially binds to the neurokinin-1 receptor (NK-1R), another GPCR that is

expressed and upregulated in cholangiocytes following BDL<sup>101</sup>. In a NK-1R knockout mouse model (NK-1R<sup>-/-</sup>), Glaser et al. demonstrated that loss of the NK-1R receptor was associated with increased biliary apoptosis, decreased serum transaminases, and decreased expression of fibrotic genes following BDL<sup>101</sup>. Targeting SP or NK-1R may lead to treatment strategies for cholangiopathies and other chronic inflammatory liver conditions.

*Nerve Growth Factor.* Similar to other hormones, NGF has been shown to enhance biliary proliferation during cholestatic liver disease. Gigliozzi et al. showed that NGF is secreted from cholangiocytes, and expression of the peptide and its receptor (TrkA) is upregulated following BDL<sup>102</sup>. NGF stimulated cholangiocyte proliferation in vitro through AKT and ERK1/2 pathways, whereas neutralizing NGF following BDL decreased biliary proliferation<sup>102</sup>.

*Melatonin.* Melatonin, primarily secreted from the pineal gland, the synthesis of which is regulated by the rate-limiting enzyme arylalkylamine *N*-acetyltransferase (AANAT), has also been shown to regulate cholangiocyte proliferation during cholestasis<sup>103</sup>. Large cholangiocytes express melatonin receptors (MT1 and MT2) as well as circadian locomotor output cycles kaput (Clock) genes<sup>104</sup>. These receptors and Clock genes are upregulated following BDL. Administration of melatonin to BDL rats significantly decreased bile duct mass in vivo and cholangiocyte proliferation in vitro by activating the MT1 receptor, decreasing cAMP levels and PKA phosphorylation<sup>104</sup>. These effects were inhibited in the presence of a melatonin receptor antagonist<sup>104</sup>. An additional study using BDL rats showed that melatonin decreases biliary fibrosis by decreasing oxidative stress during cholestasis<sup>105</sup>.

In a more recent study, Renzi et al. further characterized melatonin's role in cholangiocyte proliferation during cholestasis. This study demonstrated that cholangiocytes express AANAT and secrete melatonin, both of which are increased following BDL<sup>106</sup>. Inhibition of AANAT expression using Vivo-Morpholinos increased biliary proliferation and expression of SR, CFTR, and Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> AE2<sup>106</sup>. A recent review by Glaser et al. provides a comprehensive evaluation of melatonin's protective effects against liver injury in BDL, as well as other models, such as acetaminophen toxicity, nonalcoholic fatty liver disease (NAFLD), and ischemia/reperfusion injury<sup>103</sup>. It is clear that melatonin and the regulation of Clock genes play significant roles in liver injury; however, more studies are needed to develop appropriate therapeutic strategies for liver disease.

### Sex Hormones

Many sex hormones, specifically estrogen and progesterone, stimulate a variety of cells to proliferate. The effects of sex hormones and their role in cholangiocyte

proliferation have also been studied in the biliary epithelium. Many studies have evaluated the mechanisms by which estrogen and progesterone regulate cholangiocyte proliferation, but more recently, other sex hormones such as follicle-stimulating hormone (FSH) and gonadotropin-releasing hormone (GnRH) have become known for their involvement in cholangiocyte proliferation during cholestasis. The mechanisms by which these hormones regulate cholangiocyte proliferation will be reviewed in the following sections.

*Estrogens.* Alvaro et al. first demonstrated that cholangiocytes express the estrogen receptor (ER)  $\alpha$  and  $\beta$  subtypes<sup>107</sup>. Immunoreactivity and receptor expression of the ER- $\beta$  subtypes were significantly upregulated in BDL rats, more so than the ER- $\alpha$  subtype<sup>107</sup>. Treatment of BDL rats with tamoxifen inhibited cholangiocyte proliferation and increased cholangiocyte apoptosis, which was also replicated in vitro<sup>107</sup>. Treatment of cholangiocytes with 17- $\beta$ -estradiol stimulates cholangiocyte proliferation by activation of the Src/Shc/ERK pathway, a response that is diminished by cotreatment with inhibitors of this pathway<sup>108</sup>. Furthermore, Alvaro et al. demonstrated that rats that underwent bilateral oophorectomy + BDL showed decreased cholangiocyte expression of ER- $\alpha$  and ER- $\beta$  receptors, markedly reduced cholangiocyte proliferation, and increased cholangiocyte apoptosis compared to BDL-only rats<sup>109</sup>. Treatment of the oophorectomy rats with 17- $\beta$ -estradiol restored normal biliary response to BDL<sup>109</sup>. These studies led to an interest in using tamoxifen for the treatment of PBC, and in a small retrospective review, patients with PBC treated with tamoxifen for breast cancer showed improved liver enzymes compared to other PBC patients<sup>110</sup>. Cholangiocytes from PBC patients express both ER subtypes, and their expression becomes markedly reduced in advanced-stage PBC, which correlates with the degree of ductopenia<sup>102</sup>. These findings, however, have not led to a recent advance in PBC treatment, and research for utilizing sex hormones for treating cholangiopathies is lacking.

*Progesterone.* In addition to estrogen, progesterone has also been shown to regulate cholangiocyte proliferation during cholestasis. Cholangiocytes express the nuclear progesterone receptor (PR-B) and several membrane receptors (PRGMC1, PRGMC2, and mPR $\alpha$ )<sup>111</sup>. Treatment of rats with progesterone increased the number of bile ducts, and treatment of BDL rats with anti-progesterone antibodies inhibited cholangiocyte proliferation<sup>111</sup>. The study also demonstrated that cholangiocytes express the progesterone biosynthetic pathway and secrete progesterone<sup>111</sup>.

*Follicle-Stimulating Hormone.* FSH is a sex hormone primarily secreted from the anterior pituitary gland that increases cAMP/adenylyl cyclase/PKA phosphorylation through interactions with a GPCR to stimulate estrogen

secretion from the ovaries<sup>112</sup>. Mancinelli et al. demonstrated that cholangiocytes express the FSH receptor (FSHR) and secrete FSH, which stimulates cholangiocyte growth by increasing cAMP and ERK1/2 and Elk-1 phosphorylation<sup>113</sup>. Administration of anti-FSH antibodies to BDL rats significantly reduced bile duct mass, cholangiocyte proliferation, secretin-induced cAMP levels, and ERK1/2 and Elk-1 phosphorylation<sup>113</sup>.

*Gonadotropin-Releasing Hormone.* Additionally, GnRH is another sex hormone that has been shown to regulate cholangiocyte proliferation via autocrine/paracrine mechanisms. Traditionally, GnRH is secreted from the hypothalamus and stimulates FSH/luteinizing hormone (LH) from the anterior pituitary gland<sup>114</sup>. GnRH interacts with two receptor subtypes: GnRHR<sub>1</sub> and GnRHR<sub>2</sub><sup>114</sup>. Ray et al. demonstrated that these receptors are expressed by cholangiocytes, and GnRH is secreted from cholangiocytes, which is increased in response to BDL<sup>115</sup>. Disruption of the GnRH/GnRHR interaction decreased cholangiocyte proliferation, bile duct mass, and liver fibrosis following BDL<sup>115</sup>. These recent findings make additional contributions to the growing field of sex hormones and their impacts on cell proliferation outside of the reproductive system. All of these findings suggest that sex hormones are important for cholangiocyte proliferation during cholestasis; however, widespread utilization of these pathways for cholangiopathy treatment is not established.

*Prolactin.* Prolactin is also a hormone secreted from the anterior pituitary gland that promotes proliferation of several cell types by interacting with two receptor subtypes, a long form and a short form<sup>116</sup>. Taffetani et al. showed that normal cholangiocytes express both receptor subtypes, which are upregulated following BDL<sup>116</sup>. Stimulation of these receptors promotes cholangiocyte proliferation via increased intracellular Ca<sup>2+</sup> and PKC-β1 phosphorylation and decreased PKC-α phosphorylation<sup>116</sup>. Administration of anti-prolactin antibodies decreased cholangiocyte proliferation following BDL.

#### *Other Moderators of Cholangiocyte Proliferation*

Many other hormones have demonstrated effects on cholangiocyte proliferation during cholestasis, further expanding our knowledge about their neuroendocrine phenotypes. Fava et al. demonstrated that cholangiocytes express the thyroid hormone receptor (THR)<sup>117</sup>. These receptors were located in the cytoplasm of normal cholangiocytes, but only the α<sub>1</sub> and α<sub>2</sub> subunits were found in the nucleus following BDL<sup>117</sup>. Administration of 3,3',5-L-tri-iodothyronine (T3) decreased cholangiocyte proliferation following BDL by PLC/IP<sub>3</sub>/Ca<sup>2+</sup>-dependent decreased phosphorylation of Src/ERK1/2<sup>117</sup>. This study indicates that THR expression and location may be implicated in the pathogenesis of cholestatic liver disease.

The renin–angiotensin system (RAS) is another neuroendocrine pathway that has profound effects on cholangiocyte proliferation and cholestatic liver injury. In a recent study, Afroze et al. discovered that renin, angiotensin-converting enzyme, angiotensinogen, and angiotensin receptor type 1 are expressed by cholangiocytes and upregulated following BDL in rats<sup>118</sup>. Treatment of cholangiocytes in vitro with angiotensin II increased proliferation, intracellular cAMP, and activation of PKA/ERK/CREB signaling pathway<sup>118</sup>. In vivo angiotensin II treatment following BDL also promoted expression of genes corresponding with hepatic fibrosis [fibronectin 1, collagen 1A1, and interleukin-6 (IL-6)]<sup>118</sup>. Treatment of BDL rats with losartan attenuated biliary proliferation and expression of these fibrotic markers<sup>118</sup>. These findings indicate that cholangiocytes express a local RAS pathway that promotes cholangiocyte proliferation and fibrosis from cholestatic liver injury.

Furthermore, environmental exposures, such as nicotine, have also been implicated in cholangiocyte proliferation. In a recent study, Jensen et al. demonstrated that cholangiocytes express the α7 nicotinic acetylcholine receptor (α7-nAChR)<sup>119</sup>. Chronic stimulation of this receptor with nicotine in rats using osmotic minipumps for 2 weeks stimulated ERK1/2-dependent cholangiocyte proliferation and expression of fibrotic genes, such as fibronectin-1 and α-smooth muscle actin<sup>119</sup>. Further studies are needed to determine how chronic nicotine exposure correlates with cholestatic liver injury and cholangiopathies, but these results demonstrate that environmental exposures may also contribute to cholangiocyte proliferation and fibrosis.

### **LINKING CHOLANGIOCYTE PROLIFERATION WITH PORTAL FIBROSIS**


Ductular reaction is a common term in literature that refers to the classical findings of cholestatic liver injury: increased number of biliary ductules accompanied by polymorphonuclear leukocytes and extracellular matrix that results in portal fibrosis and biliary cirrhosis<sup>120</sup>. Proliferating cholangiocytes respond to a number of local and systemic moderators during cholestasis. Additional studies have demonstrated that proliferating cholangiocytes express many antiapoptotic genes, adhesion molecules, costimulatory molecules, cytokines, chemokines, growth factors, and profibrogenic stimuli<sup>121</sup>. These factors have autocrine and paracrine effects on myofibroblast activation, migration, and proliferation<sup>121</sup>. Figure 3 provides a working model of the interactions between cholangiocytes and fibroblasts during cholestasis.

Targeting the αvβ<sub>6</sub> integrin that is secreted from proliferating cholangiocytes has led to promising antifibrotic effects during cholestasis. It has been widely described that αvβ<sub>6</sub> binds to and activates TGF-β1 during cholestasis,

which promotes activation of myofibroblasts and ductular reaction<sup>122</sup>. Genetically altered  $\beta 6$ -null mice display decreased hepatic fibrosis when subjected to cholestasis<sup>122</sup>. A recent study from Pi et al. demonstrated that  $\text{av}\beta_6$  is closely associated with connective tissue growth factor (CTGF) during cholestasis and may serve as therapeutic targets to control ductular reaction and fibrosis since they interact with common matrix and signaling partners, such as fibronectin and TGF- $\beta 1$ <sup>123</sup>. Targeting specific growth factors and integrins that are secreted from proliferating cholangiocytes and promote activation of myofibroblasts may lead to promising therapies to reduce ductular reaction during cholestasis.

#### *Additional Pathways of Proliferation and Fibrosis*

In addition to numerous growth factors and neuroendocrine molecules, recent studies have identified other pathways that contribute to biliary proliferation and the development of fibrosis during cholestasis. Omenetti et al. first described that the hedgehog (Hh) pathway promotes cross-talk between myofibroblastic cells and cholangiocytes in BDL mice. They demonstrated increased expression of Hh ligands and target genes in hepatic stellate cells and cholangiocytes following BDL<sup>124</sup>. Coculture of these cells resulted in increased Hh ligand expression, cell viability, and proliferation. Administration of Hh ligand-neutralizing antibodies reversed these effects<sup>124</sup>.



**Figure 3.** Proliferating cholangiocytes secrete cytokines, chemokines, growth factors, and costimulatory molecules that act via auto-crine/paracrine mechanisms to interact with other cholangiocytes and activate fibroblasts, which initiates fibrogenesis.

Furthermore, activation of the Hh pathway following BDL-induced cholestatic liver injury promotes cholangiocyte secretion of cytokines, specifically chemokine motif ligand 16 (Cxcl16), which recruits natural killer cells to portal tracts and further propagates the inflammatory process<sup>125</sup>. Additionally, the Hh pathway has been shown to activate osteopontin, a profibrogenic extracellular matrix protein, in a murine model of nonalcoholic steatohepatitis (NASH)<sup>126</sup>. Recent studies have also shown that osteopontin mediates the inflammatory processes during cholestasis by initiating neutrophil-mediated injury following BDL in mice<sup>127</sup>. All of these studies suggest that the Hh pathway mediates the proliferative, inflammatory, and fibrogenic response to cholestatic liver injury.

Additionally, Cheng et al. demonstrated that Wnt signaling promotes activation of hepatic stellate cells and liver fibrosis. Inhibition of Wnt signaling with Dickkopf-1, a Wnt coreceptor antagonist, restores stellate cells to a quiescent state in vitro and ameliorates liver fibrosis in vivo<sup>128</sup>. Furthermore, Wnt signaling has been shown to regulate proliferation of cholangiocarcinoma, a malignancy of the biliary epithelium, and antagonizing this pathway decreases cholangiocarcinoma proliferation and tumor growth<sup>129,130</sup>. More studies are needed to determine the links between Wnt signaling, cholangiocyte proliferation, and portal fibrosis during cholestasis; however, it does appear that this pathway is capable of propagating liver injury.

Recently Zhang et al. has shown that Notch signaling contributes to the differentiation of hepatic progenitor cells into cholangiocytes following BDL in rats. Inhibition of Notch signaling with DAPT, a  $\gamma$ -secretase inhibitor, blocked expression of cholangiocyte-specific markers, cholangiocyte proliferation, and cholestatic liver fibrosis<sup>131</sup>. These recent insights into Hh, Wnt, and Notch signaling pathways represent potential novel therapeutic targets into the management of cholestatic liver disease, but more research is needed to determine the feasibility of targeting these pathways for future clinical trials.

#### *Inflammation as a Contributor to Hepatic Fibrosis*

Recent studies have shown that inflammatory cells also contribute to the pathogenesis of liver fibrosis. Österreicher et al. characterized human and animal liver cells positive for fibroblast-specific protein 1 (FSP1), a marker of fibroblasts. They identified a subset of FSP1<sup>+</sup> inflammatory macrophages that were present in liver injury, fibrosis, and cancer<sup>132</sup>. These cells also expressed COX2 and osteopontin, as well as inflammatory chemokines and cytokines<sup>132</sup>. Furthermore, the interplay between hepatic stellate cells and macrophages has also been linked to Notch signaling. Bansal et al. demonstrated that inhibition of Notch signaling with a  $\gamma$ -secretase inhibitor significantly attenuated CCl<sub>4</sub>-induced liver fibrosis by decreasing stellate cell activation,

inhibiting M1 inflammatory macrophages, and increasing M2-suppressive macrophages<sup>133</sup>. Furthermore, Locatelli et al. used a mouse model of congenital hepatic fibrosis to demonstrate that a genetically induced biliary epithelial dysfunction promotes the secretion of chemokines able to recruit macrophages that generate a profibrotic tissue response in an effort to create a reparative phenotype<sup>134</sup>.

#### **CONCLUSIONS AND FUTURE DIRECTIONS**

In this review, we have highlighted cholangiocyte anatomy, physiology, and the heterogeneity that exists within the biliary tree. Using multiple mechanisms of cholestasis, researchers over the past two decades have broadly described multiple mechanisms and pathways that stimulate cholangiocyte proliferation and ductular reactions during cholestasis. These models are pivotal to understand the pathogenesis of cholangiopathies, such as PBC and PSC, as well as primary cilia disorders, such as polycystic liver disease. There is growing evidence that proliferating cholangiocytes secrete a number of factors, including hormones, neuropeptides, and growth factors, that act via autocrine/paracrine mechanisms to activate fibroblasts and promote liver fibrosis in response to cholestasis. Additional studies are needed to target these mechanisms of cholangiocyte proliferation and secretion to develop pharmacologic therapies against these conditions. Based on the research discussed in this review, it may be possible to antagonize the pathways that promote cholangiocyte proliferation with receptor-specific antagonists. Our current understanding of cholangiocyte proliferation and fibrosis suggests that treatments to decrease cholangiocyte proliferation may also decrease the secretion of cytokines, chemokines, and other factors that drive hepatic fibrosis in cholestatic liver injury.

*ACKNOWLEDGMENTS: This work was supported in part by the Dr. Nicholas C. Hightower Centennial Chair of Gastroenterology from Scott & White, a VA Research Career Scientist Award, a VA Merit award to Dr. Alpini (5I01BX000574), a VA Merit Award (5I01BX002192) to Dr. Glaser, a VA Merit Award (1I01BX001724) to Dr. Meng from the US Department of Veterans Affairs Biomedical Laboratory Research, and National Institutes of Health grants DK058411, DK076898, DK107310, and DK062975 to Drs. Alpini, Meng, and Glaser. This material is the result of work supported by resources at the Central Texas Veterans Health Care System. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.*

#### **REFERENCES**

1. Juza RM, Pauli EM. Clinical and surgical anatomy of the liver: A review for clinicians. *Clin Anat*. 2014;27(5):764–9.
2. Malarkey DE, Johnson K, Ryan L, Boorman G, Maronpot RR. New insights into functional aspects of liver morphology. *Toxicol Pathol*. 2005;33(1):27–34.
3. Kanno N, LeSage G, Glaser S, Alvaro D, Alpini G. Functional heterogeneity of the intrahepatic biliary epithelium. *Hepatology* 2000;31(3):555–61.

4. Nathanson MH, Boyer JL. Mechanisms and regulation of bile secretion. *Hepatology* 1991;14(3):551–66.
5. Kanz M. Anatomy and physiology of the biliary epithelium. In: McQueen CA, editor. *Comprehensive toxicology*, 2nd ed. New York (NY): Elsevier; 2010. p. 43–108.
6. Kanno N, LeSage G, Glaser S, Alpini G. Regulation of cholangiocyte bicarbonate secretion. *Am J Physiol Gastrointest Liver Physiol*. 2001;281(3):G612–25.
7. Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. *J Clin Invest*. 1988;81(2):569–78.
8. Glaser S, Gaudio E, Miller T, Alvaro D, Alpini G. Cholangiocyte proliferation and liver fibrosis. *Expert Rev Mol Med*. 2009;11:e7.
9. Glaser S, Gaudio E, Rao A, Pierce LM, Onori P, Franchitto A, Francis HL, Dostal DE, Venter JK, DeMorrow S, Mancinelli R, Carpino G, Alvaro D, Kopriva SE, Savage JM, Alpini GD. Morphological and functional heterogeneity of the mouse intrahepatic biliary epithelium. *Lab Invest*. 2009;89(4):456–69.
10. Alpini G, Franchitto A, Demorrow S, Onori P, Gaudio E, Wise C, Francis H, Venter J, Kopriva S, Mancinelli R and others. Activation of alpha(1)-adrenergic receptors stimulate the growth of small mouse cholangiocytes via calcium-dependent activation of nuclear factor of activated T cells 2 and specificity protein 1. *Hepatology* 2011;53(2):628–39.
11. Alpini G, Glaser S, Robertson W, Rodgers RE, Phinzy JL, Lasater J, LeSage G. Large but not small intrahepatic bile ducts are involved in secretin-regulated ductal bile secretion. *Am J Physiol Gastrointest Liver Physiol*. 1997;272(5 Pt 1):G1064–74.
12. Alpini G, Glaser S, Ueno Y, Pham L, Podila PV, Caligiuri A, LeSage G, LaRusso NF. Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. *Am J Physiol Gastrointest Liver Physiol*. 1998;274(4 Pt 1):G767–75.
13. Alpini G, Roberts S, Kuntz SM, Ueno Y, Gubba S, Podila PV, LeSage G, LaRusso NF. Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. *Gastroenterology* 1996;110(5):1636–43.
14. Schaffner F, Popper H. Electron microscopic studies of normal and proliferated bile ductules. *Am J Pathol*. 1961;38:393–410.
15. Steiner JW, Carruthers JS. Studies on the fine structure of the terminal branches of the biliary tree: I. The morphology of normal bile canaliculi, bile pre-ductules (ducts of Hering) and bile ductules. *Am J Pathol*. 1961;38(6):639–61.
16. Benedetti A, Bassotti C, Rapino K, Marucci L, Jezequel AM. A morphometric study of the epithelium lining the rat intrahepatic biliary tree. *J Hepatol*. 1996;24(3):335–42.
17. Alpini G, Glaser S, Baiocchi L, Francis H, Xia X, LeSage G. Secretin activation of the apical Na<sup>+</sup>-dependent bile acid transporter is associated with cholehepatic shunting in rats. *Hepatology* 2005;41(5):1037–45.
18. Glaser S, Meng F, Han Y, Onori P, Chow BK, Francis H, Venter J, McDaniel K, Marzioni M, Invernizzi P, Ueno Y, Lai JM, Huang L, Standeford H, Alvaro D, Gaudio E, Franchitto A, Alpini G. Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and microRNA let7a in mice. *Gastroenterology* 2014;146(7):1795–808 e12.
19. Alpini G, Prall RT, LaRusso NF. The pathobiology of biliary epithelia. In: Arias IM, Boyer JL, Chisari FV, Fausto N, Jakoby W, Schachter D, Shafritz DA, editors. *The liver: Biology & pathobiology*, 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2001. p. 421–35.
20. Han Y, Glaser S, Meng F, Francis H, Marzioni M, McDaniel K, Alvaro D, Venter J, Carpino G, Onori P, Gaudio E, Alpini G, Franchitto A. Recent advances in the morphological and functional heterogeneity of the biliary epithelium. *Exp Biol Med*. (Maywood) 2013;238(5):549–65.
21. Mancinelli R, Franchitto A, Gaudio E, Onori P, Glaser S, Francis H, Venter J, Demorrow S, Carpino G, Kopriva S, White M, Fava G, Alvaro D, Alpini G. After damage of large bile ducts by gamma-aminobutyric acid, small ducts replenish the biliary tree by amplification of calcium-dependent signaling and de novo acquisition of large cholangiocyte phenotypes. *Am J Pathol*. 2010;176(4):1790–800.
22. Mancinelli R, Franchitto A, Glaser S, Meng F, Onori P, DeMorrow S, Francis H, Venter J, Carpino G, Baker K, Han Y, Ueno Y, Gaudio E, Alpini G. GABA induces the differentiation of small into large cholangiocytes by activation of Ca<sup>2+</sup>/CaMK I-dependent adenylyl cyclase 8. *Hepatology* 2013;58(1):251–63.
23. Francis HL, DeMorrow S, Franchitto A, Venter JK, Mancinelli RA, White MA, Meng F, Ueno Y, Carpino G, Renzi A, Baker KK, Shine HE, Francis TC, Gaudio E, Alpini GD, Onori P. Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP<sub>3</sub>/Ca<sup>2+</sup> and cAMP-dependent signaling mechanisms. *Lab Invest*. 2012;92(2):282–94.
24. Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, LaRusso NF. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. *Hepatology* 2014;59(6):2263–75.
25. Sasaki M, Ikeda H, Yamaguchi J, Nakada S, Nakanuma Y. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence. *Hepatology* 2008;48(1):186–95.
26. Farouk M, Vigna SR, Haebig JE, Gettys TW, McVey DC, Chari R, Pruthi RS, Meyers WC. Secretin receptors in a new preparation of plasma membranes from intrahepatic biliary epithelium. *J Surg Res*. 1993;54(1):1–6.
27. Alpini G, Ulrich CD 2nd, Phillips JO, Pham LD, Miller LJ, LaRusso NF. Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation. *Am J Physiol Gastrointest Liver Physiol*. 1994;266(5 Pt 1):G922–8.
28. Alvaro D, Mennone A, Boyer JL. Role of kinases and phosphatases in the regulation of fluid secretion and Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange in cholangiocytes. *Am J Physiol Gastrointest Liver Physiol*. 1997;273(2 Pt 1):G303–13.
29. Strazzabosco M, Fiorotto R, Melero S, Glaser S, Francis H, Spirli C, Alpini G. Differentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation. *Hepatology* 2009;50(1):244–52.
30. McGill JM, Basavappa S, Gettys TW, Fitz JG. Secretin activates Cl<sup>-</sup> channels in bile duct epithelial cells through a cAMP-dependent mechanism. *Am J Physiol Gastrointest Liver Physiol*. 1994;266(4 Pt 1):G731–6.
31. Martinez-Anso E, Castillo JE, Diez J, Medina JF, Prieto J. Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. *Hepatology* 1994;19(6):1400–6.

32. Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U. A biliary HCO<sub>3</sub><sup>-</sup> umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. *Hepatology* 2012;55(1):173–83.
33. Francis H, Glaser S, Ueno Y, Lesage G, Marucci L, Benedetti A, Taffetani S, Marzioni M, Alvaro D, Venter J and others. cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. *J Hepatol.* 2004;41(4):528–37.
34. Werneburg NW, Yoon JH, Higuchi H, Gores GJ. Bile acids activate EGF receptor via a TGF- $\alpha$ -dependent mechanism in human cholangiocyte cell lines. *Am J Physiol Gastrointest Liver Physiol.* 2003;285(1):G31–6.
35. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. *J Hepatol.* 2004;41(5):808–14.
36. Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, Wang Y, Deng G, Zhu L, Tan Z and others. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. *PLoS One* 2011; 6(1):e15640.
37. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. *Hepatology* 2009;50(6):1861–70.
38. Larusso NF, Masyuk TV. The role of cilia in the regulation of bile flow. *Dig Dis.* 2011;29(1):6–12.
39. Dutta AK, Woo K, Khimji AK, Kresge C, Feranchak AP. Mechanosensitive Cl<sup>-</sup> secretion in biliary epithelium mediated through TMEM16A. *Am J Physiol Gastrointest Liver Physiol.* 2013;304(1):G87–98.
40. Masyuk AI, Gradilone SA, Banales JM, Huang BQ, Masyuk TV, Lee SO, Splinter PL, Stroope AJ, Larusso NF. Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. *Am J Physiol Gastrointest Liver Physiol.* 2008;295(4):G725–34.
41. LeSage G, Benedetti A, Glaser S, Marucci L, Tretjak Z, Caligiuri A, Rodgers R, Phinizy JL, Baiocchi L, Francis H, Lasater J, Ugili L, Alpini G. Acute carbon tetrachloride feeding selectively damages large, but not small, cholangiocytes from normal rat liver. *Hepatology* 1999;29(2):307–19.
42. Alpini G, Elias I, Glaser S, Rodgers RE, Phinizy JL, Robertson WE, Francis H, Lasater J, Richards M, LeSage G. Gamma-Interferon inhibits secretin-induced cholestasis and cholangiocyte proliferation in a murine model of cirrhosis. *J Hepatol.* 1997;27(2):371–80.
43. Alpini G, Glaser S, Ueno Y, Rodgers R, Phinizy JL, Francis H, Baiocchi L, Holcomb LA, Caligiuri A, LeSage G. Bile acid feeding induces cholangiocyte proliferation and secretion: Evidence for bile acid-regulated ductal secretion. *Gastroenterology* 1999;116(1):179–86.
44. LeSage G, Glaser S, Gubba S, Robertson WE, Phinizy JL, Lasater J, Rodgers RE, Alpini G. Regrowth of the rat biliary tree after 70% partial hepatectomy is coupled to increased secretin-induced ductal secretion. *Gastroenterology* 1996;111(6):1633–44.
45. Fickert P, Wagner M, Marschall HU, Fuchsichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. *Gastroenterology* 2006;130(2):465–81.
46. Alvaro D, Mancino MG, Glaser S, Gaudio E, Marzioni M, Francis H, Alpini G. Proliferating cholangiocytes: A neuroendocrine compartment in the diseased liver. *Gastroenterology* 2007;132(1):415–31.
47. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: Disorders of biliary epithelia. *Gastroenterology* 2004;127(5):1565–77.
48. Glaser S, Lam IP, Franchitto A, Gaudio E, Onori P, Chow BK, Wise C, Kopriva S, Venter J, White M, Ueno Y, Dostal D, Carpino G, Mancinelli R, Butler W, Chiasson V, DeMorrow S, Francis H, Alpini G. Knockout of secretin receptor reduces large cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct ligation. *Hepatology* 2010;52(1):204–14.
49. Guerrier M, Attili F, Alpini G, Glaser S. Prolonged administration of secretin to normal rats increases biliary proliferation and secretin-induced ductal secretory activity. *Hepatobiliary Surg Nutr.* 2014;3(3):118–25.
50. Glaser S, Meng F, Wu N, Venter J, Kyritsi K, Alpini G. The secretin receptor antagonist (SCT 5-27) reduces biliary hyperplasia and liver fibrosis in an animal model of primary sclerosing cholangitis. *FASEB J.* 2016;30(1 Suppl):56.7.
51. Wu N, Meng F, Invernizzi P, Bernuzzi F, Venter J, Standeford H, Onori P, Marzioni M, Alvaro D, Franchitto A, Gaudio E, Glaser S, Alpini G. The secretin/secretin receptor axis modulates liver fibrosis through changes in TGF- $\beta$ 1 biliary secretion. *Hepatology* 2016;64(3): 865–79.
52. Tietz PS, Alpini G, Pham LD, LaRusso NF. Somatostatin inhibits secretin-induced ductal hyperchloresis and exocytosis by cholangiocytes. *Am J Physiol Gastrointest Liver Physiol.* 1995;269(1 Pt 1):G110–8.
53. Glaser S, Benedetti A, Marucci L, Alvaro D, Baiocchi L, Kanno N, Caligiuri A, Phinizy JL, Chowdury U, Papa E, LeSage G, Alpini G. Gastrin inhibits cholangiocyte growth in bile duct-ligated rats by interaction with cholecystokinin-B/Gastrin receptors via D-myo-inositol 1,4,5-triphosphate-, Ca(2+)-, and protein kinase C alpha-dependent mechanisms. *Hepatology* 2000;32(1):17–25.
54. Tracy TF Jr, Tector AJ, Goerke ME, Kitchen S, Lagunoff D. Somatostatin analogue (octreotide) inhibits bile duct epithelial cell proliferation and fibrosis after extrahepatic biliary obstruction. *Am J Pathol.* 1993;143(6):1574–8.
55. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. *Gastroenterology* 2007;132(3):1104–16.
56. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenti P. Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide. *Clin J Am Soc Nephrol.* 2010;5(5):783–9.
57. Walsh JH. Role of gastrin as a trophic hormone. *Digestion* 1990;47(Suppl 1):11–6; discussion 49–52.
58. Glaser S, Alvaro D, Ueno Y, Francis H, Marzioni M, Phinizy JL, Baumann B, Mancino MG, Venter J, LeSage G, Alpini G. Gastrin reverses established cholangiocyte proliferation and enhanced secretin-stimulated ductal secretion of BDL rats by activation of apoptosis through

- increased expression of Ca<sup>2+</sup>-dependent PKC isoforms. *Liver Int.* 2003;23(2):78–88.
59. Drucker DJ. Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. *Mol Endocrinol.* 2003;17(2):161–71.
  60. Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Glaser S, Benedetti A. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. *Gastroenterology* 2007;133(1):244–55.
  61. Marzioni M, Fava G, Alvaro D, Alpini G, Benedetti A. Control of cholangiocyte adaptive responses by visceral hormones and neuropeptides. *Clin Rev Allergy Immunol.* 2009;36(1):13–22.
  62. Alpini G, Glaser S, Robertson W, Phinizy JL, Rodgers RE, Caligiuri A, LeSage G. Bile acids stimulate proliferative and secretory events in large but not small cholangiocytes. *Am J Physiol Gastrointest Liver Physiol.* 1997;273(2 Pt 1):G518–29.
  63. Alpini G, Ueno Y, Glaser S, Marzioni M, Phinizy JL, Francis H, LeSage G. Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes. *Hepatology* 2001;34(5):868–76.
  64. Alpini G, Glaser S, Alvaro D, Ueno Y, Marzioni M, Francis H, Baiocchi L, Stati T, Barbaro B, Phinizy JL, Mauldin J, LeSage G. Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats. *Gastroenterology* 2002;123(4):1226–37.
  65. Alpini G, Baiocchi L, Glaser S, Ueno Y, Marzioni M, Francis H, Phinizy JL, Angelico M, LeSage G. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. *Hepatology* 2002;35(5):1041–52.
  66. Marzioni M, Francis H, Benedetti A, Ueno Y, Fava G, Venter J, Reichenbach R, Mancino MG, Summers R, Alpini G, Glaser S. Ca<sup>2+</sup>-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. *Am J Pathol.* 2006;168(2):398–409.
  67. Williamson KD, Chapman RW. New therapeutic strategies for primary sclerosing cholangitis. *Semin Liver Dis.* 2016;36(1):5–14.
  68. Corpechot C. Primary biliary cirrhosis beyond ursodeoxycholic acid. *Semin Liver Dis.* 2016;36(1):15–26.
  69. Gaudio E, Franchitto A, Pannarale L, Carpino G, Alpini G, Francis H, Glaser S, Alvaro D, Onori P. Cholangiocytes and blood supply. *World J Gastroenterol.* 2006;12(22):3546–52.
  70. Gaudio E, Barbaro B, Alvaro D, Glaser S, Francis H, Ueno Y, Meininger CJ, Franchitto A, Onori P, Marzioni M, Taffetani S, Fava G, Stoica G, Venter J, Reichenbach R, De Morrow S, Summers R, Alpini G. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. *Gastroenterology* 2006;130(4):1270–82.
  71. Gaudio E, Barbaro B, Alvaro D, Glaser S, Francis H, Franchitto A, Onori P, Ueno Y, Marzioni M, Fava G, Venter J, Reichenbach R, Summers R, Alpini G. Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. *Am J Physiol Gastrointest Liver Physiol.* 2006;291(2):G307–17.
  72. Mancinelli R, Onori P, Gaudio E, Franchitto A, Carpino G, Ueno Y, Alvaro D, Annarale LP, Demorrows S, Francis H. Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression. *Exp Biol Med.* (Maywood) 2009;234(4):462–74.
  73. Fabris L, Cadamuro M, Fiorotto R, Roskams T, Spirli C, Melero S, Sonzogni A, Joplin RE, Okolicsanyi L, Strazzabosco M. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. *Hepatology* 2006;43(5):1001–12.
  74. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB. VEGF receptor inhibition blocks liver cyst growth in *pkd2*(WS25<sup>-/-</sup>) mice. *Am J Physiol Cell Physiol.* 2007;293(1):C419–28.
  75. Morell CM, Fabris L, Strazzabosco M. Vascular biology of the biliary epithelium. *J Gastroenterol Hepatol.* 2013;28(Suppl 1):26–32.
  76. Wang L, Wang X, Xie G, Wang L, Hill CK, DeLeve LD. Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats. *J Clin Invest.* 2012;122(4):1567–73.
  77. Wang L, Wang X, Wang L, Chiu JD, van de Ven G, Gaarde WA, Deleve LD. Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells. *Gastroenterology* 2012;143(6):1555–1563 e2.
  78. DeLeve LD, Wang X, Wang L. VEGF-sdf1 recruitment of CXCR7+ bone marrow progenitors of liver sinusoidal endothelial cells promotes rat liver regeneration. *Am J Physiol Gastrointest Liver Physiol.* 2016;ajpgi 00056 2016.
  79. Fabris L, Cadamuro M, Libbrecht L, Raynaud P, Spirli C, Fiorotto R, Okolicsanyi L, Lemaigre F, Strazzabosco M, Roskams T. Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. *Hepatology* 2008;47(2):719–28.
  80. Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Lopez-Cabrera M, Moreno-Otero R. Evidence of angiogenesis in primary biliary cirrhosis: An immunohistochemical descriptive study. *J Hepatol.* 2005;42(1):124–31.
  81. Pinzani M, Milani S, Herbst H, DeFranco R, Grappone C, Gentilini A, Caligiuri A, Pellegrini G, Ngo DV, Romanelli RG, Gentilini P. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. *Am J Pathol.* 1996;148(3):785–800.
  82. Grappone C, Pinzani M, Parola M, Pellegrini G, Caligiuri A, DeFranco R, Marra F, Herbst H, Alpini G, Milani S. Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. *J Hepatol.* 1999;31(1):100–9.
  83. Kinnman N, Hultcrantz R, Barbu V, Rey C, Wendum D, Poupon R, Housset C. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. *Lab Invest.* 2000;80(5):697–707.
  84. Kinnman N, Francoz C, Barbu V, Wendum D, Rey C, Hultcrantz R, Poupon R, Housset C. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. *Lab Invest.* 2003;83(2):163–73.
  85. Kocabayoglu P, Lade A, Lee YA, Dragomir AC, Sun X, Fiel MI, Thung S, Aloman C, Soriano P, Hoshida Y, Friedman SL.  $\beta$ -PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. *J Hepatol.* 2015;63(1):141–7.

86. Alvaro D, Alpini G, Jezequel AM, Bassotti C, Francia C, Fraioli F, Romeo R, Marucci L, Le Sage G, Glaser S, Benedetti A. Role and mechanisms of action of acetylcholine in the regulation of rat cholangiocyte secretory functions. *J Clin Invest.* 1997;100(6):1349–62.
87. LeSage E, Alvaro D, Benedetti A, Glaser S, Marucci L, Baiocchi L, Eisel W, Caligiuri A, Phinizy JL, Rodgers R, Francis H, Alpini G. Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. *Gastroenterology* 1999;117(1):191–9.
88. Iwai M, Shimazu T. Alteration in sympathetic nerve activity during liver regeneration in rats after partial hepatectomy. *J Auton Nerv Syst.* 1992;41(3):209–14.
89. Glaser S, Alvaro D, Francis H, Ueno Y, Marucci L, Benedetti A, De Morrow S, Marzioni M, Mancino MG, Phinizy JL, Reichenbach R, Fava G, Summers R, Venter J, Alpini G. Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. *Am J Physiol Gastrointest Liver Physiol.* 2006;290(4):G813–26.
90. Glaser S, Alvaro D, Roskams T, Phinizy JL, Stoica G, Francis H, Ueno Y, Barbaro B, Marzioni M, Mauldin J, Rashid S, Mancino MG, LeSage G, Alpini G. Dopaminergic inhibition of secretin-stimulated choleresis by increased PKC-gamma expression and decrease of PKA activity. *Am J Physiol Gastrointest Liver Physiol.* 2003;284(4):G683–94.
91. Coufal M, Invernizzi P, Gaudio E, Bernuzzi F, Frampton GA, Onori P, Franchitto A, Carpino G, Ramirez JC, Alvaro D, Marzioni M, Battisti G, Benedetti A, DeMorrow S. Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. *Int J Cancer* 2010;126(9):2112–22.
92. Marzioni M, Glaser S, Francis H, Marucci L, Benedetti A, Alvaro D, Taffetani S, Ueno Y, Roskams T, Phinizy JL, Venter J, Fava G, LeSage GD, Alpini G. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. *Gastroenterology* 2005;128(1):121–37.
93. Omenetti A, Yang L, Gainetdinov RR, Guy CD, Choi SS, Chen W, Caron MG, Diehl AM. Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults. *Am J Physiol Gastrointest Liver Physiol.* 2011;300(2):G303–15.
94. Mann DA, Oakley F. Serotonin paracrine signaling in tissue fibrosis. *Biochim Biophys Acta* 2013;1832(7):905–10.
95. Francis H, Franchitto A, Ueno Y, Glaser S, DeMorrow S, Venter J, Gaudio E, Alvaro D, Fava G, Marzioni M, Vaculin B, Alpini G. H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. *Lab Invest.* 2007;87(5):473–87.
96. Graf A, Meng F, Hargrove L, Kennedy L, Han Y, Francis T, Hodges K, Ueno Y, Nguyen Q, Greene JF, Francis H. Knockout of histidine decarboxylase decreases bile duct ligation-induced biliary hyperplasia via downregulation of the histidine decarboxylase/VEGF axis through PKA-ERK1/2 signaling. *Am J Physiol Gastrointest Liver Physiol.* 2014;307(8):G813–23.
97. Kennedy LL, Hargrove LA, Graf AB, Francis TC, Hodges KM, Nguyen QP, Ueno Y, Greene JF, Meng F, Huynh VD, Francis HL. Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents. *Lab Invest.* 2014;94(12):1406–18.
98. Francis H, Glaser S, Demorrow S, Gaudio E, Ueno Y, Venter J, Dostal D, Onori P, Franchitto A, Marzioni M, Vaculin B, Vaculin B, Katki K, Stutes M, Savage J, Alpini G. Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. *Am J Physiol Cell Physiol.* 2008;295(2):C499–513.
99. Johnson C, Hargrove L, Graf A, Kennedy L, Hodges K, Harris R, Francis T, Ueno Y, Francis H. Histamine restores biliary mass following carbon tetrachloride-induced damage in a cholestatic rat model. *Dig Liver Dis.* 2015;47(3):211–7.
100. Glaser S, Ueno Y, DeMorrow S, Chiasson VL, Katki KA, Venter J, Francis HL, Dickerson IM, DiPette DJ, Supowit SC, Alpini GD. Knockout of alpha-calcitonin gene-related peptide reduces cholangiocyte proliferation in bile duct ligated mice. *Lab Invest.* 2007;87(9):914–26.
101. Glaser S, Gaudio E, Renzi A, Mancinelli R, Ueno Y, Venter J, White M, Kopriva S, Chiasson V, DeMorrow S, Francis H, Meng F, Marzioni M, Franchitto A, Alvaro D, Supowit S, DiPette DJ, Onori P, Alpini G. Knockout of the neurokinin-1 receptor reduces cholangiocyte proliferation in bile duct-ligated mice. *Am J Physiol Gastrointest Liver Physiol.* 2011;301(2):G297–305.
102. Gigliozzi A, Alpini G, Baroni GS, Marucci L, Metalli VD, Glaser S, Francis H, Mancino MG, Ueno Y, Barbaro B, Benedetti A, Attili AF, Alvaro D. Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. *Gastroenterology* 2004;127(4):1198–209.
103. Glaser S, Han Y, Francis H, Alpini G. Melatonin regulation of biliary functions. *Hepatobiliary Surg Nutr.* 2014;3(1):35–43.
104. Renzi A, Glaser S, DeMorrow S, Mancinelli R, Meng F, Franchitto A, Venter J, White M, Francis H, Han Y, Alvaro D, Gaudio E, Carpino G, Ueno Y, Onori P, Alpini G. Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors. *Am J Physiol Gastrointest Liver Physiol.* 2011;301(4):G634–43.
105. Aktas C, Kanter M, Erboga M, Mete R, Oran M. Melatonin attenuates oxidative stress, liver damage and hepatocyte apoptosis after bile-duct ligation in rats. *Toxicol Ind Health* 2014;30(9):835–44.
106. Renzi A, DeMorrow S, Onori P, Carpino G, Mancinelli R, Meng F, Venter J, White M, Franchitto A, Francis H, Han Y, Ueno Y, Dusio G, Jensen KJ, Greene JJ Jr, Glaser S, Gaudio E, Alpini G. Modulation of the biliary expression of arylalkylamine N-acetyltransferase alters the autocrine proliferative responses of cholangiocytes in rats. *Hepatology* 2013;57(3):1130–41.
107. Alvaro D, Alpini G, Onori P, Perego L, Svegliata Baroni G, Franchitto A, Baiocchi L, Glaser SS, Le Sage G, Folli F, Gaudio E. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. *Gastroenterology* 2000;119(6):1681–91.
108. Alvaro D, Onori P, Metalli VD, Svegliati-Baroni G, Folli F, Franchitto A, Alpini G, Mancino MG, Attili AF, Gaudio E. Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. *Hepatology* 2002;36(2):297–304.
109. Alvaro D, Gigliozzi A, Attili AF, Onori P, Franchitto A, Vetuschchi A, Glaser S, Le Sage G, Alpini G, Morini S, Gaudio E. Effect of ovariectomy on the proliferative capacity of

- intrahepatic rat cholangiocytes. *Gastroenterology* 2002; 123(1):336–44.
110. Invernizzi P, Alvaro D, Crosignani A, Gaudio E, Podda M. Tamoxifen in treatment of primary biliary cirrhosis. *Hepatology* 2004;39(4):1175–6.
  111. Glaser S, DeMorrow S, Francis H, Ueno Y, Gaudio E, Vaculin S, Venter J, Franchitto A, Onori P, Vaculin B, Marzioni M, Wise C, Pилanthanonnd M, Savage J, Pierce L, Mancinelli R, Alpini G. Progesterone stimulates the proliferation of female and male cholangiocytes via autocrine/paracrine mechanisms. *Am J Physiol Gastrointest Liver Physiol*. 2008;295(1):G124–G136.
  112. Ulloa-Aguirre A, Zarinan T, Pasapera AM, Casas-Gonzalez P, Dias JA. Multiple facets of follicle-stimulating hormone receptor function. *Endocrine* 2007;32(3):251–63.
  113. Mancinelli R, Onori P, Gaudio E, DeMorrow S, Franchitto A, Francis H, Glaser S, Carpino G, Venter J, Alvaro D, Kopriva S, White M, Kossie A, Savage J, Alpini G. Follicle-stimulating hormone increases cholangiocyte proliferation by an autocrine mechanism via cAMP-dependent phosphorylation of ERK1/2 and Elk-1. *Am J Physiol Gastrointest Liver Physiol*. 2009;297(1):G11–26.
  114. Harrison GS, Wierman ME, Nett TM, Glode LM. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. *Endocr Relat Cancer* 2004; 11(4):725–48.
  115. Ray D, Han Y, Franchitto A, DeMorrow S, Meng F, Venter J, McMillin M, Kennedy L, Francis H, Onori P, Mancinelli R, Gaudio E, Alpini G, Glaser SS. Gonadotropin-releasing hormone stimulates biliary proliferation by paracrine/autocrine mechanisms. *Am J Pathol*. 2015;185(4):1061–72.
  116. Taffetani S, Glaser S, Francis H, DeMorrow S, Ueno Y, Alvaro D, Marucci L, Marzioni M, Fava G, Venter J, Vaculin S, Vaculin B, Lam IP, Lee VH, Gaudio E, Carpino G, Benedetti A, Alpini G. Prolactin stimulates the proliferation of normal female cholangiocytes by differential regulation of Ca<sup>2+</sup>-dependent PKC isoforms. *BMC Physiol*. 2007;7:6.
  117. Fava G, Ueno Y, Glaser S, Francis H, DeMorrow S, Marucci L, Marzioni M, Benedetti A, Venter J, Vaculin B, Vaculin S, Alpini G. Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP(3)/Ca(2+)-dependent downregulation of SRC/ERK1/2. *Am J Physiol Cell Physiol*. 2007;292(4):C1467–75.
  118. Afroze SH, Munshi MK, Martine AK, Uddin M, Gergely M, Szykarski C, Guerrier M, Nizamutdinov D, Dostal D, Glaser S. Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation. *Am J Physiol Gastrointest Liver Physiol*. 2015;308(8):G691–701.
  119. Jensen K, Afroze S, Ueno Y, Rahal K, Frenzel A, Sterling M, Guerrier M, Nizamutdinov D, Dostal DE, Meng F, Glasser SS. Chronic nicotine exposure stimulates biliary growth and fibrosis in normal rats. *Dig Liver Dis*. 2013;45(9):754–61.
  120. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. *Semin Diagn Pathol*. 1998;15(4):259–69.
  121. Penz-Osterreicher M, Osterreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. *Best Pract Res Clin Gastroenterol*. 2011;25(2):245–58.
  122. Wang B, Dolinski BM, Kikuchi N, Leone DR, Peters MG, Weinreb PH, Violette SM, Bissell DM. Role of alphavbeta6 integrin in acute biliary fibrosis. *Hepatology* 2007;46(5):1404–12.
  123. Pi L, Robinson PM, Jorgensen M, Oh SH, Brown AR, Weinreb PH, Trinh TL, Yianni P, Liu C, Leask A, Violette SM, Scott EW, Schultz GS, Petersen BE. Connective tissue growth factor and integrin  $\alpha v \beta 6$ : A new pair of regulators critical for ductular reaction and biliary fibrosis in mice. *Hepatology* 2015;61(2):678–91.
  124. Omenetti A, Yang L, Li YX, McCall SJ, Jung Y, Sicklick JK, Huang J, Choi S, Suzuki A, Diehl AM. Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. *Lab Invest*. 2007;87(5):499–514.
  125. Omenetti A, Syn WK, Jung Y, Francis H, Porrello A, Witek RP, Choi SS, Yang L, Mayo MJ, Gershwin ME, Alpini G, Diehl AM. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. *Hepatology* 2009;50(2):518–27.
  126. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Abdelmalek MF, Guy CD, Adams DH, Kuo PC, Michelotti GA, Whittington PF, Diehl AM. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. *Hepatology* 2011;53(1):106–15.
  127. Yang M, Ramachandran A, Yan HM, Woolbright BL, Cople BL, Fickert P, Trauner M, Jaeschke H. Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. *Toxicol Lett*. 2014;224(2):186–95.
  128. Cheng JH, She H, Han YP, Wang J, Xiong S, Asahina K, Tsukamoto H. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. *Am J Physiol Gastrointest Liver Physiol*. 2008;294(1):G39–49.
  129. Boulter L, Guest RV, Kendall TJ, Wilson DH, Wojtacha D, Robson AJ, Ridgway RA, Samuel K, Van Rooijen N, Barry ST, Wigmore SJ, Sansom OJ, Forbes SJ. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. *J Clin Invest*. 2015;125(3):1269–85.
  130. Zhang KS, Zhou Q, Wang YF, Liang LJ. Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells. *Oncol Rep*. 2013;30(3):1430–8.
  131. Zhang X, Du G, Xu Y, Li X, Fan W, Chen J, Liu C, Chen G, Liu C, Zern MA, Mu Y, Liu P. Inhibition of notch signaling pathway prevents cholestatic liver fibrosis by decreasing the differentiation of hepatic progenitor cells into cholangiocytes. *Lab Invest*. 2016;96(3):350–60.
  132. Osterreicher CH, Penz-Osterreicher M, Grivnenkov SI, Guma M, Koltsova EK, Datz C, Sasik R, Hardiman G, Karin M, Brenner DA. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. *Proc Natl Acad Sci USA*. 2011;108(1):308–13.
  133. Bansal R, van Baarlen J, Storm G, Prakash J. The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. *Sci Rep*. 2015;5:18272.
  134. Locatelli L, Cadamuro M, Spirli C, Fiorotto R, Lecchi S, Morell CM, Popov Y, Scirpo R, De Matteis M, Amenduni M, Pietrobattista A, Torre G, Schuppan D, Fabris L, Strazzabosco M. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. *Hepatology* 2016;63(3):965–82.